CD20
Antibody
|
Total No. infected
|
No. Hospitalised
|
No.
Intensive Care
|
No.
Deaths
|
Reference
|
Ocrelizumab |
1 |
1 |
0 |
0 |
36 |
Ocrelizumab |
1 |
1 |
0 |
0 |
37 |
Ocrelizumab |
2 |
0 |
0 |
0 |
38 |
Ocrelizumab |
34 |
2 |
0 |
0 |
39 |
Ocrelizumab |
100 |
26 |
5 |
N.R. |
40 |
Ocrelizumab |
1 |
1 |
0 |
0 |
41 |
Ocrelizumab |
1 |
0 |
0 |
0 |
42 |
Ocrelizumab |
11 |
5 |
2 |
N.R. |
43 |
Ocrelizumab |
26 |
N.R. |
2 |
0 |
44 |
Ocrelizumab |
59 |
N.R. |
N.R. |
2 |
45 |
Ocrelizumab |
10 |
N.R. |
N.R. |
N.R. |
46 |
Ocrelizumab |
2 |
0 |
0 |
0 |
47 |
Ocrelizumab |
25 |
7 |
2 |
0 |
48 |
Ocrelizumab |
7 |
3 |
0 |
0 |
49 |
Subtotal |
280 |
45 |
11 |
2 |
|
Rituximab |
2 |
N.R. |
1 |
1 |
44 |
Rituximab |
7 |
1 |
0 |
0 |
38 |
Rituximab |
21 |
≤2 |
0 |
0 |
39 |
Rituximab |
1 |
1 |
1 |
1 |
50 |
Rituximab |
41 |
9 |
6 |
N.R. |
51 |
Rituximab |
6 |
N.R. |
N.R. |
N.R. |
46 |
Rituximab |
9 |
N.R. |
N.R. |
0 |
45 |
Rituximab |
24 |
8 |
5 |
1 |
48 |
Subtotal |
111 |
21 |
13 |
3 |
|
Ofatumumab |
1 |
0 |
0 |
0 |
48 |
Total |
392 |
64 |
24 |
5 |
|